Back
PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification
Journal article

PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification

  • Missiaglia, Edoardo Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Williamson, Dan Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Chisholm, Julia Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Wirapati, Pratyaksha Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Pierron, Gaëlle Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Petel, Fabien Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Concordet, Jean-Paul Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Thway, Khin Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Oberlin, Odile Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Pritchard-Jones, Kathy Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Delattre, Olivier Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Delorenzi, Mauro Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
  • Shipley, Janet Edoardo Missiaglia, Pratyaksha Wirapati, and Mauro Delorenzi, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Edoardo Missiaglia, Khin Thway, and Janet Shipley, The Institute of Cancer Research, Sutton, Surrey; Dan Williamson, Northern Institute for Cancer Research, Newcastle upon Tyne; Julia Chisholm and Khin Thway, Royal Marsden National Health Service Foundation Trust, Sutton; Kathy Pritchard-Jones, University College London Institute of Child Health, London, United Kingdom; Gaëlle Pierron,...
Show more…
Published in:
  • Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2012, vol. 30, no. 14, p. 1670-1677
Cancer Research
Oncology
English Purpose To improve the risk stratification of patients with rhabdomyosarcoma (RMS) through the use of clinical and molecular biologic data. Patients and Methods Two independent data sets of gene-expression profiling for 124 and 101 patients with RMS were used to derive prognostic gene signatures by using a meta-analysis. These and a previously published metagene signature were evaluated by using cross validation analyses. A combined clinical and molecular risk-stratification scheme that incorporated the PAX3/FOXO1 fusion gene status was derived from 287 patients with RMS and evaluated. Results We showed that our prognostic gene-expression signature and the one previously published performed well with reproducible and significant effects. However, their effect was reduced when cross validated or tested in independent data and did not add new prognostic information over the fusion gene status, which is simpler to assay. Among nonmetastatic patients, patients who were PAX3/FOXO1 positive had a significantly poorer outcome compared with both alveolar-negative and PAX7/FOXO1-positive patients. Furthermore, a new clinicomolecular risk score that incorporated fusion gene status (negative and PAX3/FOXO1 and PAX7/FOXO1 positive), Intergroup Rhabdomyosarcoma Study TNM stage, and age showed a significant increase in performance over the current risk-stratification scheme. Conclusion Gene signatures can improve current stratification of patients with RMS but will require complex assays to be developed and extensive validation before clinical application. A significant majority of their prognostic value was encapsulated by the fusion gene status. A continuous risk score derived from the combination of clinical parameters with the presence or absence of PAX3/FOXO1 represents a robust approach to improving current risk-adapted therapy for RMS.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/280738
Statistics
Document views: 22 File downloads: